Katherine Baicker elected to Lilly’s board of directors
pharmafile | December 12, 2011 | Appointment | Business Services, Research and Development, Sales and Marketing | lilly
Lilly has elected Katherine Baicker as a new member of its board of directors, effective immediately.
Baicker, 40, is Professor of health economics in the department of health policy and management at the Harvard School of Public Health.
As a member of Lilly’s board, Professor Baicker will serve on the public policy and compliance committee. She will serve under interim election and will stand for election by Lilly shareholders at the company’s annual meeting in April next year.
John Lechleiter, Lilly’s chairman, president and chief executive officer, said: “I am very pleased to welcome Kate Baicker to the Lilly board.”
Prior to her current position at the Harvard School of Public Health, Professor Baicker served as a Senate-confirmed member of the President’s council of economic advisers from 2005 – 2007, where she played a leading role in the development of health policy.
Related Content
NICE RECOMMENDS LILLY’S TIRZEPATIDE (MOUNJARO ®▼) FOR MANAGING OVERWEIGHT AND OBESITY IN FINAL DRAFT GUIDANCE
BASINGSTOKE, 5th December 2024 – Eli Lilly and Company announced today that the National Institute …

Lilly’s COVID-19 drug has EUA revoked in favour of combination therapy
The FDA have revoked Emergency Use Authorization (EUA) of Eli Lilly’s bamlanivimab drug for the …

Lilly’s ulcerative colitis treatment meets all key endpoints in Phase III trial
Eli Lilly’s mirikizumab treatment for ulcerative colitis (UC) patients has met the primary endpoints and …






